Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029961 | 1.00 | PDE4B (0.43) | PDE4BAVPR1BADRB2PRKAA2KDM4E | |
| SCHEMBL3023140 | 0.94 | PDE4B (0.47) | PDE4BAVPR1BADRB2PRKAA2ACKR3 | |
| SCHEMBL3030814 | 0.91 | AVPR1B (0.41) | PDE4BAVPR1BADRB2 | |
| SCHEMBL3030807 | 0.91 | AVPR1B (0.41) | PDE4BAVPR1BADRB2 | |
| SCHEMBL871179 | 0.91 | PDE4B (0.46) | PDE4BPRKAA2ACKR3CNR2 | |
| SCHEMBL871178 | 0.91 | PDE4B (0.46) | PDE4BPRKAA2ACKR3CNR2 | |
| SCHEMBL3029083 | 0.90 | ACVR1 (0.40) | PDE4BAVPR1BADRB2PRKAA2DRD2 | |
| SCHEMBL3029088 | 0.90 | ACVR1 (0.40) | PDE4BAVPR1BADRB2PRKAA2DRD2 | |
| SCHEMBL869865 | 0.90 | PDE4B (0.47) | PDE4BPRKAA2ACKR3CNR2 | |
| SCHEMBL869866 | 0.90 | PDE4B (0.47) | PDE4BPRKAA2ACKR3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PDE4B 2/4885AVPR1B 1234/4885ADRB2 105/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | PDE4B 2/4885AVPR1B 1852/4885ADRB2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.